Cargando…

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)

PURPOSE OF REVIEW: This review aims to summarize the most recent published literature concerning lomitapide and volanesorsen that are approved for the use in HoFH and FCS patients, respectively. Moreover, it will briefly revise the published evidence on novel, non-approved treatments that are under...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Erasmo, Laura, Bini, Simone, Arca, Marcello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Nonstatin Drugs (M. Vrablik, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410715/ https://www.ncbi.nlm.nih.gov/pubmed/34468855 http://dx.doi.org/10.1007/s11883-021-00967-8

Ejemplares similares

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020)

Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey
por: Walzer, S, et al.
Publicado: (2013)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting
por: Mahzari, Moeber, et al.
Publicado: (2021)

Case Report: Liver Transplantation in Homozygous Familial Hypercholesterolemia (HoFH)—Long-Term Follow-Up of a Patient and Literature Review
por: Mlinaric, Matej, et al.
Publicado: (2020)

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
por: Fruchart, Jean-Charles, et al.
Publicado: (2020)

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020)

RNA Silencing in the Management of Dyslipidemias
por: Henney, Neil C., et al.
Publicado: (2021)

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021)

Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
por: Parhofer, Klaus G.
Publicado: (2021)

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022)

Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study
por: Nohara, Atsushi, et al.
Publicado: (2019)

Identifying Patients with Familial Chylomicronemia Syndrome Using FCS Score-Based Data Mining Methods
por: Németh, Ákos, et al.
Publicado: (2022)

Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28
por: Kaiser, Karen, et al.
Publicado: (2022)

Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry
por: Cuchel, Marina, et al.
Publicado: (2023)

Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia
por: Larrey, Dominique, et al.
Publicado: (2022)

Cascade Screening for Familial Hypercholesterolemia (FH)
por: Ned, Renée M., et al.
Publicado: (2011)

Correction to: Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights from the CASCADE FH Registry
Publicado: (2023)

Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score
por: Moulin, Philippe, et al.
Publicado: (2018)

Homozygous familial hypercholesterolemia
por: Parihar, Ravi Kumar, et al.
Publicado: (2012)

Homozygous Familial Hypercholesterolemia
por: Nohara, Atsushi, et al.
Publicado: (2021)

Case report: Therapy adherence, MTTP variants, and course of atheroma in two patients with HoFH on low-dose, long-term lomitapide therapy
por: Kayikcioglu, Meral, et al.
Publicado: (2023)

Familial Hypercholesterolemia (FH) in Iran: Findings from the Four-Year FH Registry
por: Vaseghi, Golnaz, et al.
Publicado: (2021)

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile
por: Lupo, Maria Giovanna, et al.
Publicado: (2021)

The Genetic Spectrum of Familial Hypercholesterolemia (FH) in the Iranian Population
por: Fairoozy, R. H., et al.
Publicado: (2017)

The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry
por: Alallaf, Faisal, et al.
Publicado: (2017)

Familial homozygous hypercholesterolemia with arcus cornea and xanthomas: A rare but serious entity
por: Chamli, Amal, et al.
Publicado: (2023)

Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan
por: Mabuchi, Hiroshi
Publicado: (2017)

Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents
por: Cohen, Hofit, et al.
Publicado: (2021)

Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FH(Marburg) (FH p.W556R)
por: Schaefer, Juergen R., et al.
Publicado: (2012)

Xanthoma tuberosum in homozygous familial hypercholesterolemia
por: Moorthy, Nagaraja, et al.
Publicado: (2014)

Liver Transplantation for Homozygous Familial Hypercholesterolemia
por: Ishigaki, Yasushi, et al.
Publicado: (2019)

Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab
por: Jeraj, Natasha, et al.
Publicado: (2021)

Advancements in the Treatment of Homozygous Familial Hypercholesterolemia
por: Bajaj, Archna, et al.
Publicado: (2022)

Collaborative Approach to Reach Everyone with Familial Hypercholesterolemia: CARE-FH Protocol
por: Jones, Laney K., et al.
Publicado: (2022)

Shortcomings on genetic testing of Familial hypercholesterolemia (FH) in India: Can we collaborate to establish Indian FH registry?
por: Reddy, Lakshmi Lavanya, et al.
Publicado: (2022)

Surgical Management and Outcomes of Homozygous Familial Hypercholesterolemia in Two Cousins: A Rare Case Report
por: Alenizi, Mutaz M, et al.
Publicado: (2020)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_aci72501bsrfph32099mmqj2ol